NDANASALSPRAY
Approved
Apr 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
3/8 — Basic
REZENOPY (naloxone hcl) by Hikma is sites. First approved in 2024.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
REZENOPY (naloxone HCL) is a nasal spray formulation of naloxone, an opioid antagonist approved in April 2024. It reverses acute opioid overdose by blocking opioid receptors and restoring normal respiration, consciousness, and blood pressure. The drug addresses a critical public health need in opioid addiction and overdose management.
Growth14.6 years to LOE
Early-stage commercial launch presents opportunities to build market share in the rapidly expanding opioid reversal market with competitive pressures currently absent.
Mechanism of Action
sites. Administration of naloxone hydrochloride reverses the effects of opioids, including respiratory depression, sedation and hypotension. It can also reverse the psychotomimetic and dysphoric effects of agonist-antagonists such as pentazocine.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
REZENOPY represents a growth-stage opportunity with established efficacy and favorable patent runway through 2041. Roles align with commercial launch and market penetration in a high-impact therapeutic area addressing opioid overdose.
Brand ManagerField Sales Representative
Worked on REZENOPY at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.